Literature DB >> 23377434

Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study.

Roberto D'Alessandro1, Luca Vignatelli, Alessandra Lugaresi, Elisa Baldin, Franco Granella, Maria Rosaria Tola, Susanna Malagù, Luisa Motti, Walter Neri, Massimo Galeotti, Mario Santangelo, Laila Fiorani, Enrico Montanari, Cinzia Scandellari, Maria Donata Benedetti, Maurizio Leone.   

Abstract

The aim of the study was to estimate the rate of conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS) and to investigate variables predicting conversion in a cohort of patients presenting with symptoms suggestive of MS. Patients with a first symptom suggestive of MS in the preceding 6 months and exclusion of other diseases were enrolled in an observational prospective study from December 2004 through June 2007. Conversion from CIS to MS according to both McDonald and Clinically Defined Multiple Sclerosis (CDMS) criteria was prospectively recorded until March 2010. The multivariate Cox proportional hazard model was used to assess the best predictive factors of conversion from CIS to MS. Among 168 patients included in the analysis, 122 converted to MS according to McDonald criteria whereas 81 converted to MS according to CDMS criteria. The 2-year probability of conversion was 57% for McDonald Criteria and 36% for CDMS criteria. Variables at enrolment significantly associated with conversion according to McDonald criteria were age and positivity for Barkhof criteria, and according to Poser's CDMS criteria, age, positivity for Barkhof criteria and no disease modifying therapy. In this large prospective cohort study the conversion rate from CIS to MS in patients presenting with recent symptoms suggestive of MS was within the range of previous observational studies and lower than that reported in the placebo arm of randomized trials. We confirm the prognostic value of MRI in addition to the previous experimental data on the protective role of disease-modifying therapies.

Entities:  

Mesh:

Year:  2013        PMID: 23377434     DOI: 10.1007/s00415-013-6838-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  28 in total

1.  Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis.

Authors:  M Tintoré; A Rovira; M J Martínez; J Rio; P Díaz-Villoslada; L Brieva; C Borrás; E Grivé; J Capellades; X Montalban
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

2.  Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings.

Authors:  J Sastre-Garriga; M Tintoré; A Rovira; E Grivé; I Pericot; M Comabella; A J Thompson; X Montalban
Journal:  Mult Scler       Date:  2003-02       Impact factor: 6.312

3.  Brainstem lesions in clinically isolated syndromes.

Authors:  M Tintore; A Rovira; G Arrambide; R Mitjana; J Río; C Auger; C Nos; M C Edo; J Castilló; A Horga; F Perez-Miralles; E Huerga; M Comabella; J Sastre-Garriga; X Montalban
Journal:  Neurology       Date:  2010-11-23       Impact factor: 9.910

4.  A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis.

Authors:  E Paolino; E Fainardi; P Ruppi; M R Tola; V Govoni; I Casetta; V C Monetti; E Granieri; M Carreras
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-05       Impact factor: 10.154

5.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Authors:  G Comi; M Filippi; F Barkhof; L Durelli; G Edan; O Fernández; H Hartung; P Seeldrayers; P S Sørensen; M Rovaris; V Martinelli; O R Hommes
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

6.  MRI only conversion to multiple sclerosis following a clinically isolated syndrome.

Authors:  D T Chard; C M Dalton; J Swanton; L K Fisniku; K A Miszkiel; A J Thompson; G T Plant; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-06-02       Impact factor: 10.154

Review 7.  Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis.

Authors:  David Miller; Frederik Barkhof; Xavier Montalban; Alan Thompson; Massimo Filippi
Journal:  Lancet Neurol       Date:  2005-05       Impact factor: 44.182

8.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

Authors:  L Kappos; C H Polman; M S Freedman; G Edan; H P Hartung; D H Miller; X Montalban; F Barkhof; L Bauer; P Jakobs; C Pohl; R Sandbrink
Journal:  Neurology       Date:  2006-08-16       Impact factor: 9.910

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  8 in total

1.  Assessing subjective quality of life domains after multiple sclerosis diagnosis disclosure.

Authors:  Katia Mattarozzi; Federica Casini; Elisa Baldin; Martina Baldini; Alessandra Lugaresi; Paola Milani; Erika Pietrolongo; Alberto Gajofatto; Maurizio Leone; Trond Riise; Luca Vignatelli; Roberto D'Alessandro
Journal:  Health Expect       Date:  2015-04-24       Impact factor: 3.377

2.  Predicting onset of secondary-progressive multiple sclerosis using genetic and non-genetic factors.

Authors:  Elina Misicka; Corriene Sept; Farren B S Briggs
Journal:  J Neurol       Date:  2020-04-24       Impact factor: 4.849

Review 3.  [Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017].

Authors:  O Aktas; M P Wattjes; M Stangel; H-P Hartung
Journal:  Nervenarzt       Date:  2018-12       Impact factor: 1.214

4.  Predictors of disability worsening in clinically isolated syndrome.

Authors:  Vilija G Jokubaitis; Tim Spelman; Tomas Kalincik; Guillermo Izquierdo; François Grand'Maison; Pierre Duquette; Marc Girard; Alessandra Lugaresi; Pierre Grammond; Raymond Hupperts; José Cabrera-Gomez; Celia Oreja-Guevara; Cavit Boz; Giorgio Giuliani; Ricardo Fernández-Bolaños; Gerardo Iuliano; Jeannette Lechner-Scott; Freek Verheul; Vincent van Pesch; Tatjana Petkovska-Boskova; Marcela Fiol; Fraser Moore; Edgardo Cristiano; Raed Alroughani; Roberto Bergamaschi; Michael Barnett; Mark Slee; Norbert Vella; Joseph Herbert; Cameron Shaw; Maria Laura Saladino; Maria Pia Amato; Danny Liew; Damiano Paolicelli; Helmut Butzkueven; Maria Trojano
Journal:  Ann Clin Transl Neurol       Date:  2015-03-27       Impact factor: 4.511

5.  Permeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosis.

Authors:  Stig P Cramer; Signe Modvig; Helle J Simonsen; Jette L Frederiksen; Henrik B W Larsson
Journal:  Brain       Date:  2015-07-17       Impact factor: 13.501

6.  Free kappa light chains in cerebrospinal fluid as a biomarker to assess risk conversion to multiple sclerosis.

Authors:  P Menéndez-Valladares; M I García-Sánchez; P Cuadri Benítez; M Lucas; M Adorna Martínez; V Carranco Galán; J L García De Veas Silva; C Bermudo Guitarte; G Izquierdo Ayuso
Journal:  Mult Scler J Exp Transl Clin       Date:  2015-12-16

7.  Conversion of clinically isolated syndrome to multiple sclerosis: a prospective multi-center study in Eastern India.

Authors:  T K Banerjee; M Saha; E Ghosh; A Hazra; A Das; D Choudhury; S Ojha; A Haldar; A Mukherjee; S S Nandi; A Ghosh; A Mukherjee; A Chatterjee; A Datta; S Purakayastha
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-05-13

8.  A multi-biomarker follow-up study of patients with multiple sclerosis.

Authors:  Morten Stilund; Mikkel Carstensen Gjelstrup; Tove Christensen; Holger Jon Møller; Thor Petersen
Journal:  Brain Behav       Date:  2016-07-11       Impact factor: 2.708

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.